Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
Researchers at Rockefeller University publish new data on monoclonal antibodies
May 28th, 2008
According to a study from the United States, "The induction of effective immune responses to tumor vaccines requires the preferential activation of effector T cells relative to regulatory or suppressive T cells. Glial tumors commonly overexpress the epidermal growth factor receptor (EGFR), which can be targeted by monoclonal antibodies." "Here we show that the coating of glial tumor cells with a clinical grade anti-EGFR antibody, cetuximab, leads to enhanced tumor-specific, interferon-gamma producing CD8(+) T cells by dendritic cells (DCs). The selective targeting of monoclonal antibody coated glioma cells to activating Fey receptors (Fc gamma Rs) on DCs, which is...
Source: Vaccine Weekly (2008-05-28)
|
